We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Guided Therapeutics Inc (QB) | USOTC:GTHP | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.022935 | -17.25% | 0.11 | 0.10 | 0.14 | 0.133 | 0.133 | 0.133 | 10,001 | 22:20:00 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event) March 30, 2012; (March 27, 2012)
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 0-22179 | 58-2029543 |
( State or Other Jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
Incorporation) |
5835 Peachtree Corners East, Suite D Norcross, Georgia (Address of Principal Executive Offices) |
30092 (Zip Code) |
Registrant's Telephone Number, Including Area Code: (770) 242-8723
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Section 2.02 Results of Operations and Financial Condition
On March 28, 2012, the registrant publicly released its financial results for the fourth quarter and full year ended December 31, 2011, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.
Section 7.01 (Regulation FD Disclosure)
On March 29, 2012, the registrant conducted a conference call discussing its financial results for the fourth quarter and full year ended December 31, 2011 and other matters concerning the operation of the company, as more fully described in the prepared transcript of the call, a copy of which is furnished as Exhibit 99.2 hereto and which information is incorporated herein by reference.
On March 27, 2012, the registrant publicly issued a press release announcing that the company had selected three companies to distribute the LuViva® Advanced Cervical Scan in six European territories, as more fully described in the press release, a copy of which is furnished as Exhibit 99.3 hereto and which information is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number | E xhibit |
99.1 | Press Release dated March 28, 2012 |
99.2 | Transcript |
99.3 | Press Release dated March 27, 2012 |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUIDED THERAPEUTICS, INC . | |||
By: | /s/ Mark L. Faupel, Ph.D. | ||
Mark L. Faupel, Ph.D. | |||
CEO & President | |||
Date: March 30, 2012 |
3 |
1 Year Guided Therapeutics (QB) Chart |
1 Month Guided Therapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions